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ABSTRACT  
Objectives: To analyze the rationality of central nervous system fixed dose combinations used in a tertiary care hospital. Methodology: The 
study was an hospital based observational study. The data was collected from an annual drug compendium entitled “Hospital Dru g List”. Fixed 
dose combinations (FDCs) enlisted in central nervous system (CNS) sections were selected for the study purpose. The active pharmacological 
ingredients (APIs) in FDC was checked for approval by Drug Control General of India (DCGI), World Health Organization (WHO) and essential 
medicine (EML)/national essential medicine list (NEML),both or none and all the ingredients (molecule, excipients) present in the FDC was 
checked whether banned or under any controversies in India as well as worldwide.  Efficacy and safety of the individual active pharmacological 
ingredients (APIs) and their combination were searched. Details of each drug were collected [Generic name, Pharmacokinetics, Interaction 
affected, Pharmacodynamics, and Advantages of FDCs]. The data collected was analyzed by a tool to assess the rationality of fixed dose 
combinations which is pre-tested and validated by Shah et al., based on WHO guidelines. Result and Discussion: A total of 25 CNS FDCs were 
taken, on assessment of CNS FDCs 21 (84%) were found to be rational and 4 (16%) were found to be irrational with the mean rationality score 
of 7.2. By winding up, state of nonbeing, absenteeism of legality and effectiveness of the formulations appeared in to a peculiar combinations 
and inadequate practice. The approval process of these combinations by various committees should be robust.  
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INTRODUCTION 
Fixed Dose combinations (FDCs) are defined by the World 
Health Organization (WHO) as combination of two or more 
active ingredients in a fixed ratio of dose.1 FDCs must be 
shown to be safe and effective for the claimed indications 
and it cannot be assumed that benefits of the FDCs outweigh 
its risks.2 In last six years Central Drugs Standard Control 
Organization (CDSCO) has approved 303 FDCs. 3 This 
number is large when compared to the Essential Medicines 
List (EML) of WHO and national list of essential medicine 
(NEML). 4, 5As of now studies were mainly focusing on 
prescribing pattern of FDCs and their rationality. 6 
Rationality status of many fixed dose combinations 
marketed in India is not clear. The rationality of FDCs is 
based on certain aspects which are as follows, the drugs in 
the combination should act by different mechanisms, 
pharmacokinetic must not be widely different and 
combination should not have supra-additive toxicity of the 
ingredients. 
CNS drugs are the medications which are used to treat 
various neurological and psychiatric conditions. Drugs that 
act in the CNS are invaluable therapeutically. They can, e.g., 
relieve pain, reduce fever, suppress disorder movements, 
induce sleep or arousal, reduce appetite, and suppress 
nausea. Selectively acting drugs can be used to treat anxiety, 
depression, mania or schizophrenia and do so without 
altering consciousness. However, the excessive use of such 
drugs can affect lives adversely when uncontrolled, and can 
cause toxic side effects7. It is clear that nearly all drugs with 
CNS effects act on specific receptors that modulate synaptic 
transmission. While a few agents such as general anesthetics 
and alcohol may have nonspecific actions on membranes, 
even these non-receptor-mediated actions result in 
demonstrable alterations in synaptic transmission. 8 The 
CNS is responsible for processing and controlling most of 
our bodily functions, and consists of the nerves in the brain 
and spinal cord. There are many different types of drugs that 
work on the CNS, including anesthetics, anticonvulsants, 
antiemetic, antiparkinsons agents, CNS stimulants, muscle 
relaxants, narcotic analgesics, nonnarcotic analgesics and 
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sedatives. Hence there is a need to study pattern of 
prescription of these fixed dose combination drugs and 
know the rationality behind there usage. 
MATERIALS AND METHODS:  
Ethics:  
Ethical clearance was obtained from Institutional Review 
Board, Devaki Amma Memorial College of Pharmacy, 
Chelembra, Malappuram, Kerala and approved by the 
Institutional Ethics Committee, P. V. S. Hospital (P) LTD, 
Calicut, Kerala (Ref. No. PVS/EC/02/17-18). 
Study design: 
A hospital based observational study conducted from 
November 2017 to April 2018 on 25 Central nervous system 
(CNS) fixed dose combinations (FDCs) which were taken 
from PVS hospital drug compendium. 
Study Materials: 
 Hospital drug list from PVS Hospital (P) LTD, Calicut. 
 Standard reference books of pharmacology and 
medicine. 
 Authentic data base like PubMed, Medline, Google 
scholar and Cochrane data. 
 Literatures relevant to the study. 
 List of fixed dose combinations (FDCs) published by 
World Health Organization (WHO) and Drug Controller 
General of India (DCGI). 
Study Procedure: 
For the conduct of study hospital pharmacy of the study site 
was approached and the lists of the FDCs were collected 
from an annual compendium entitled “Hospital Drug List”. 
FDCs enlisted in central nervous system sections were 
collected and by Using Shah et al., pre tested validated tool 
based on WHO guidelines certain parameters were 
evaluated. 
The active pharmacological ingredient (APIs) in FDC was 
checked for approval by DCGI. If it is approved then scored 
as (+1) and if not (-1). 
All the ingredients (molecule, excipients) present in the FDC 
was determined and checked whether banned or under any 
controversies in India as well as worldwide. 
Drugs taken from the hospital list were checked whether 
they are present in WHO, essential medicine list 
(EML)/national essential medicine list (NEML), both or 
none. 
If the drug was present in both the EMLs or any one of the 
EML, score given was (+1) and if not present in any then 
scored as (0).  
Efficacy and safety information of the APIs and FDCs 
regarding these drugs was collected from the textbooks, 
reference books and authenticated websites. 
If the APIs or FDCs was safe and effective the score was (+1) 
and if not (0). 
Pharmacokinetic parameters were obtained from text books 
etc. and these parameters were used to check for interaction. 
If the interaction was favorable score was (+1), unfavorable 
(-1) and not affected score was (0). 
The pharmacodynamic interaction was reviewed and 
mechanism of action of each ingredient is checked. If similar 
mechanism of action score was (0), if different mechanism of 
action score was (+1). 
Advantages of FDCs were checked, 
a) If FDCs is more beneficial than the individual 
compound to reduce the disease then the score was 
(+1). 
b) If FDCs has lesser adverse drug reactions the score was 
(+1). 
c) If FDCs used was more convenient than individual 
compounds then the score was (+1).   
Total score obtained after assessing these parameters are 
added up, 
a) If the score was greater than or equal to seven, FDCs 
was considered as rational. 
b) If the score was less than or equal to six, FDCs was 
considered as irrational. 
RESULTS: 
The data collected was analyzed by a tool to assess the 
rationality of fixed dose combinations which is pre-tested 
and validated by Shah et al., 9 based on WHO guidelines. 
Based on the analysis the results are given in the following. 
Assessment of Rationality 
A total of 25 central nervous system fixed dose combinations 
were selected. 
Details of Active Pharmacological Ingredients 
Out of 25 CNS FDCs, 15 (60%) FDCs contained API approved 
by DCGI, in which 13 (52%) were rational and 2 (8%) were 
irrational. Remaining 10 (40%) FDCs had one or more 
unapproved API, in which 8 (32%) were rational and 2 (8%) 
were irrational. 
Table 1: Rationality of APIs in the FDC list approved by 
DCGI 
Parameters No of CNS FDCs 
(n=25) 
APIs approved by DCGI + Rational 13 (52%) 
APIs approved by DCGI + Irrational 2 (8%) 
APIs unapproved by DCGI + Rational 8 (32%) 
APIs unapproved by DCGI + Irrational 2 (8%) 
 
FDCs containing Banned/Controversial ingredients 
Out of 25 CNS FDCs assessed, 3 (12%) were found to be 
banned or controversial. 
Listing in Essential Medicine List (EML) 
Out of the 25 assessed CNS FDCs, 11 (44%) combinations 
APIs were not present in both WHO/National EML, 7 (28%) 
combinations APIs were present in either any one of the 
EML (WHO/National) and 7 (28%) combinations APIs were 
present in both the EML. 
Evidence of Efficacy and Safety of API & FDC 
Out of 25 CNS FDCs, APIs efficacy and safety of 16 (64%) 
FDCs were well documented and proved in clinical trials or 
meta-analysis. 1 (4%) FDCs had neither safe nor effective 
APIs. 
Out of 25 CNS FDCs, FDCs efficacy and safety of 16 (64%) 
were well documented and proved in clinical trials or meta-
analysis. While 1 (4%) FDCs were found to be safe but not 
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effective, 5 (20%) FDCs were found to be effective but didn’t 
show safety. 3 (12%) of the CNS FDCs was neither safe nor 
effective. 
Assessment of Pharmacokinetic and Pharmacodynamic 
interaction 
Favorable pharmacokinetic interaction was found in 5 
(20%) FDCs. No interaction between APIs was found in 20 
(80%) FDCs. 
All 25 FDCs, API had different mechanism of action. 
Advantage(s) of FDC 
Out of 25 CNS FDCs, 6 (24%) showed advantage of reducing 
Adverse Drug Reactions (ADRs) as compared to individual 
ingredient. To a great surprise, all FDCs showed advantage 
of being convenient by reducing pill count or frequency of 
administration. Also 6 (24%) of the FDCs showed advantage 
of dose reduction of individual active ingredient. 
All the above obtained data was analyzed. For the analysis 
the FDCs were categorized in to four groups. 
 
Table 2: Rationality of FDCs approved by DCGI 
Groups Description No. of CNS drugs 
A DCGI approved + Rational 16 (64%) 
B DCGI approved + Irrational 2 (8%) 
C DCGI approved + Rational 5 (20%) 
D DCGI approved + Irrational 2 (8%) 
  
On assessment of 25 CNS FDCs 21 (84%) were found to be 
rational and 4 (16%) were found to be irrational with the 
mean rationality score of 7.2 
Table 3: Assessment of CNS FDCs using Rationality Tool 
(n= 55) 
 
 
DISCUSSION 
The present study showed that a substantial number of 
rational CNS FDCs were available in the annual drug 
compendium. All though the Drug regulators of India 
prevent the manufacture, distribution, sale of irrational 
FDCs, lack of coordination with state licensing authorities 
and system to critically analyze the scientific validity has 
resulted in mushrooming of few formulations present in the 
formulary. Popularity of FDCs is increasing rapidly in case if 
more than one disease is present in patients. 
The studies showed that majority of these FDCs were 
rational and approved by DCGI. While APIs used in the 
majority of these formulations are individually approved by 
Central Regulatory authority, few FDCs contained 
unapproved APIs and found to be rational and few were 
irrational. Surprisingly, only 3 CNS FDCs (aceclofenac plus 
paracetamol, etodolac plus paracetamol, paracetamol plus 
dextropropoxyphene) were included in banned drug list 
which was present in the formulary of the Hospital. 
Availability of these FDCs raises safety concern and is 
important from a public health perspective. 
Further, evidence of efficacy and safety of individual APIs 
was found, the scientific validity of majority of CNS FDCs was 
lacking. More trials need to be conducted as some were 
lacking published articles related to the evidence of safety 
and efficacy. Safety and efficacy is of at most importance 
when two drugs are combined together as a single 
formulation.  
Similarly, certain rational CNS FDCs were combination of 
dopamine precursors etc. The combination of levodopa plus 
carbidopa increases efficacy due to pharmacokinetic 
advantage. The addition of carbidopa decreases the 
peripheral metabolism of levodopa, thereby, increasing its 
availability. 10 All the combinations were having different 
mechanism of action, which is good for rationality. But in this 
study, all criteria were used together to establish 
rationality.11 
The rationality tool also found that DCGI approved FDCs 
contain both rational and irrational FDCs. It can be 
suggested that irrational formulations can be banned or 
subjected for further efficacy and safety data. Interestingly, 
the rationality tool also showed small number of FDCs which 
were DCGI unapproved but rational, for example, tranexamic 
acid plus mefenamic acid. Due to scientific validity these 
FDCs may be considered for approved by central authorities. 
In addition, the assessment of rationality revealed that the 
mean rationality score of CNS FDCs was 7.2 more in rational 
FDCs irrespective of approval by central regulator authority. 
Thus, this further validates the rationality tool and it can be 
used by prospective researchers and regulatory body. 
The study findings confirm that few potentially harmful, 
unapproved and irrational FDCs are being used in the study 
site (Tertiary care hospital). Although the data was obtained 
from annual drug compendium and the information needed 
were obtained from standard text books and reference 
books of pharmacology and medicine, authentic data base 
like PubMed, Medline, Google scholar and Cochrane data and 
literatures relevant to the study. A possibility of lack of 
complete information cannot be ruled out. However, the 
data analyzed leads to some important conclusions. 
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Parameters 
 
CNS FDCs (n=25) 
 
DCGI Approved 
 
15 
 
Mean rationality score 
 
7.2 
 
Number of rational FDCs 
 
21 
 
Number of irrational FDCs 
 
4 
 
Number of API in each FDCs 
 
2 
 
23 
 
3 
 
2 
 
≥4 
 
0 
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